Home  > 
  Merck announces positive results from phase 3 study of non-nucleoside reverse transcriptase inhibitor, doravirine to treat HIV-1 infection,   July 27, 2017
  APPROACH trial shows experimental HIV vaccine regimen is well-tolerated and elicits immune responses,   July 26, 2017
  J&J reports positive first-in-human clinical data for investigational HIV preventive vaccine,   July 26, 2017
  Phase IIb LATTE-2 study results show comparable viral suppression rates at 96 weeks for two-drug regimen of long-acting cabotegravir & rilpivirine and three-drug regimen in patients with HIV,   July 26, 2017
  NCI-COG announces enrollment begins in Pediatric MATCH trial to test targeted drugs in childhood cancers,   July 26, 2017
  Merck's phase 3 study of Keytruda monotherapy in patients with previously treated recurrent or metastatic HNSCC fails to meet endpoint,   July 25, 2017
  BiondVax announces positive results from phase 2b trial of universal flu vaccine, M-001,   July 25, 2017
  Tiziana Life Sciences initiates phase IIa clinical trial with milciclib in patients with Hepatocellular carcinoma,   July 24, 2017
  Theravance Biopharma, Mylan report positive results from phase 3 safety study of revefenacin in patients with COPD,   July 22, 2017
  RedHill Biopharma announces last patient enrollment in BEKINDA phase II study for IBS-D,   July 22, 2017
  Kitov Pharma reports positive results from pre-clinical study of NT-219 in combo with Keytruda,   July 21, 2017
  Humabs BioMed, University of California, announce publication of data for novel antibody-based assay to detect Zika virus infection,   July 19, 2017
  BrainStorm sign pact with Massachusetts General Hospital & CPMC to participate in phase 3 trial of NurOwn in ALS,   July 19, 2017
  Novartis announces positive results from phase III long-term extension study of Cosentyx in patients with plaque psoriasis,   July 17, 2017
  Amgen's phase 3 ASPIRE study of Kyprolis to treat relapsed multiple myeloma meets key secondary endpoint,   July 14, 2017
  Boehringer Ingelheim phase III study results confirm benefit of Praxbind as reversal agent for Pradaxa patients in emergency situations,   July 13, 2017
  Sanofi Genzyme announces positive results from phase 2 OLE study with fitusiran in patients with Hemophilia A and B,   July 12, 2017
  Arena Pharma announces positive results from phase 2 study of ralinepag to treat patients with pulmonary arterial hypertension,   July 12, 2017
  PDS inks clinical collaboration with Merck to evaluate Versamune PDS0101 & Keytruda combo for metastatic head and neck cancer,   July 11, 2017
  Ionis Pharma presents positive data from phase 3 NEURO-TTR study of inotersen in patients with FAP at PNS meeting,   July 11, 2017

Copyright © 2016 Saffron Media Pvt. Ltd |